Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Rui Avelar_2023
VIEWPOINTS

Rui Avelar, CMO and Head of R&D at Evolus Shares Insights from Interim P-II Data Results Evaluating an “Extra-Strength” Formulation of Jeuveau

Shots: Rui gave the details about the “extra-strength” formulation of Jeuveau. He highlighted the study design and results of the trial evaluating  Jeuveau. The data indicated that the “extra-strength” formulation of Jeuveau at 40U achieved a duration profile of 6 months or 26 weeks The data was presented at the 2023 IMCAS World Congress in…
June 13, 2023

Read more

Insights+: EMA Marketing Authorization of New Drugs in February 2023
INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2023

Shots: The EMA approved 7 New Chemical Entity (NCE) and 5 Biologic Drugs in February 2023, leading to treatments for patients and advances in the healthcare industry In February 2023, the major highlights drugs were Forxiga’s Approval for symptomatic chronic heart failure, Fintepla for adjunctive treatment of seizures associated with lennox-gastaut syndrome PharmaShots has compiled…
March 23, 2023

Read more